Cue Biopharma公布CUE-401治疗自身免疫及炎症性疾病的临床前安全性与耐受性数据

美股速递
Feb 17

Cue Biopharma近日披露了其候选药物CUE-401针对自身免疫及炎症性疾病的临床前研究结果,重点展示了该药物在安全性和耐受性方面的积极数据。这些发现为后续临床试验的推进提供了重要依据,标志着公司在免疫疗法领域取得新进展。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10